Europe's most consequential digital legislation in years passed this week. Quantum capital keeps setting records, and Webb fingerprinted a comet from another star.
Lead
The EU Draws a Line on Cloud Dependency
The European Commission published its Technological Sovereignty Package on June 3, the most direct legislative attempt yet to reduce the bloc's dependence on foreign cloud infrastructure. Commission EVP Henna Virkkunen named the trigger: Microsoft suspended an ICC official's email account at US government request. "We want to be sure nobody has a kill switch."
The centrepiece is the Cloud and AI Development Act (CADA), which creates four sovereignty tiers for cloud use by public authorities. The highest tiers require EU ownership, EU-national staff, and structural independence from third-country legal jurisdiction. Meeting them would be effectively impossible for AWS, Azure, and Google Cloud as currently structured.
The restrictions apply to sensitive public-sector workloads: healthcare, finance, judicial systems. Private-sector cloud is not affected. What makes CADA different from prior European sovereignty announcements is the mechanism: compliance obligations, not funding incentives.
Biotech & Life Sciences
Barcelona ADC Biotech Closes $86.6M to Enter the Clinic
Ona Therapeutics, based at the Barcelona Science Park, raised an oversubscribed $86.6 million Series B on June 4, co-led by Columbus Venture Partners and Mérieux Equity Partners. Proceeds advance ONA-255, a first-in-class antibody-drug conjugate for treatment-resistant breast cancer, toward Phase 1, and begin IND-enabling work on ONA-389 for colorectal cancer.
Spain's CDTI and Ysios Capital participated alongside international backers. The round signals that Spain's biotech sector is attracting pan-European capital rather than routing founders northward.
(GlobeNewswire) (Endpoints News)
Quantum & Photonics
OQC Closes £260M in Europe's Largest Quantum Private Round
Oxford Quantum Circuits raised an oversubscribed £260 million Series C on June 3, led by Bullhound Capital. The British Business Bank anchored with £100 million, institutional capital treating quantum infrastructure as strategic rather than speculative.
It is the fourth European quantum round above $100 million this year; 2026 has already surpassed all of 2025. Funds support global deployment of OQC's superconducting systems and accelerate progress toward fault-tolerant quantum computers for finance, defence, and security.
(The Quantum Insider) (Sifted)
IQM Upsizes PIPE to $146M, Nasdaq Listing Imminent
IQM Finland upsized its SPAC merger financing to $146 million on June 2, adding Finnish pension insurer Ilmarinen as an institutional backer. The merger with Real Asset Acquisition Corp. is expected to close this month, which would make IQM the first European quantum hardware company listed on public markets, trading as IQMX on Nasdaq and dual-listed on Nasdaq Helsinki.
IQM has sold 21 quantum systems to 13 customers. Public listing shifts accountability from fundraising to commercial metrics.
Space
Webb Finds Methane on an Interstellar Comet
The James Webb Space Telescope detected methane on the interstellar comet 3I/ATLAS, published in the Astrophysical Journal Letters on June 1. The methane-to-water ratio is significantly higher than any comet formed in our Solar System, suggesting 3I/ATLAS originated in a chemically distinct stellar environment.
ESA contributes instrumentation to the Webb partnership with NASA and CSA. The observation window was narrow as the comet passed through the inner Solar System in late 2025.
The dataset now becomes a chemical baseline for interpreting any future interstellar object.
Cambridge's Tessera Puts Sentinel Data on a Laptop
ESA announced on June 4 that Tessera, a temporal foundation model from the University of Cambridge, compresses a full year of Sentinel-1 and Sentinel-2 imagery into lightweight embeddings small enough to run without cloud compute. The model was published at CVPR 2026 and developed with ESA's open innovation lab Phi-lab.
The practical effect is redistributive: organisations without large compute budgets can run land classification, crop monitoring, and fire mapping at European scale. Non-AI specialists can solve remote sensing problems globally using a fraction of the labelled data previously required.
Materials & Manufacturing
Moore4Power Launches €91M EV Power Electronics Consortium
Infineon leads Moore4Power, a €91 million, three-year Horizon Europe consortium of 62 partners from 15 countries, launched June 1. The project develops next-generation power electronics integrating silicon, silicon carbide (SiC), and gallium nitride (GaN) in chiplet architectures for electric vehicles and industrial automation.
The core problem is European dependence on Asian SiC and GaN supply chains as EV production scales. The chiplet approach should allow more flexible component sourcing, though a 62-partner consortium risks producing broad research that stops short of deployable product.
Semiconductors
Chips Act 2.0 Bets on Demand, Not Factories
Bundled into the June 3 Technological Sovereignty Package, Chips Act 2.0 shifts emphasis from supply-side manufacturing subsidies to demand aggregation, procurement coordination, and "Grand Challenges" grants to pull European industrial chip consumption into alignment for AI. A €30 billion advanced foundry at the 3nm node is under discussion, with funding split between the Commission, member states, and private capital.
The original Chips Act has underdelivered by most independent accounts: Bruegel estimated €13.75 billion in State aid approved by early 2026 against over €30 billion already deployed under the US CHIPS Act. The demand-side theory requires European industrial chip consumption to be coherent enough to aggregate. That structural question is one the new text cannot answer on its own.
(European Commission) (The Next Web)
One to Watch
MaaT Pharma's CHMP Vote: Microbiome's First European Test
MaaT Pharma received a "negative trend" opinion from the EMA's CHMP on May 20 for Xervyteg (MaaT013), its full-ecosystem microbiome therapy for acute graft-versus-host disease. The formal CHMP vote is expected this month. If negative, MaaT intends to request re-examination by a separate rapporteur panel.
MaaT013's ARES Phase 3 trial showed a 62% gastrointestinal response rate on day 28. Approval after re-examination would make it the world's first approved live biotherapeutic for an oncology indication and set a regulatory precedent for the entire microbiome product class in Europe. Watch for the formal vote outcome, likely announced in late June.